Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.
RayzeBio is a clinical-stage radiopharmaceutical therapeutics (RPT) focused on actinium-based RPTs.
Current pipeline programs are targeting the treatment of solid tumors, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), small-cell lung cancer, hepatocellular carcinoma and other cancers.
RPTs bind to tumor cells and deliver targeted radiation to ...